Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals develops immune-modulating therapies as a clinical-stage biotechnology company focused on transplant medicine and other life-threatening conditions. Its lead investigational product, tegoprubart, is an anti-CD40L antibody designed to target the CD40 Ligand pathway, with programs and study updates tied to kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis.
Company news commonly covers tegoprubart clinical data, investigator-initiated transplant studies, FDA orphan drug designations, research collaborations, conference presentations and operating results. Updates also address how the company positions CD40L modulation as a non-lymphocyte-depleting immunomodulatory approach for preventing organ rejection and supporting transplanted cell or organ grafts.
Eledon (NASDAQ: ELDN) reported updated data from a 12-patient, investigator-initiated islet transplant trial of tegoprubart in type 1 diabetes at UChicago Medicine.
According to Eledon, 100% of patients achieved insulin independence, mean HbA1c fell from ~8.0% to ~5.4%, and no severe post-transplant hypoglycemia or rejection episodes were observed over up to 22 months.
Eledon (Nasdaq: ELDN) announced that updated data from an investigator-initiated islet transplant trial of tegoprubart in patients with type 1 diabetes will be presented at the American Diabetes Association 86th Scientific Sessions on June 7, 2026, in New Orleans.
The oral presentation, titled “Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation”, will be delivered by Piotr Witkowski, M.D., Ph.D. in Session “Immune Modulatory Strategies for Next-Generation Cell Therapies,” from 2:30 p.m. to 3:00 p.m. CT in Room 343 (Level 3).
Eledon Pharmaceuticals (Nasdaq: ELDN) will present new clinical data on tegoprubart in kidney transplantation at the American Transplant Congress in Boston from June 20-24, 2026.
Presentations include updated Phase 2 BESTOW results, long-term extension data, and a June 22, 2026 investor conference call.
Eledon Pharmaceuticals (Nasdaq: ELDN) reported Q1 2026 results and key updates on tegoprubart.
All 10 evaluable type 1 diabetes patients achieved 100% insulin independence after islet transplantation. Tegoprubart received FDA Orphan Drug designation in liver transplantation. Cash was $111.1M, funding operations into 2Q 2027; Q1 net loss was $39.0M.
Eledon Pharmaceuticals (Nasdaq: ELDN) reported 2025 operational and financial results on March 19, 2026, highlighting clinical progress for tegoprubart.
Key points: FDA Orphan Drug designation for liver transplantation, 24-month kidney transplant eGFR rose from 67.0 to 74.2 mL/min/1.73 m², islet transplant results showed 10/10 patients >4 weeks insulin independent (mean HbA1c ~5.35%), R&D $66.3M, net loss $45.6M ($0.52/share); adjusted net loss $79.1M.
Eledon (NASDAQ: ELDN) reported updated investigator-initiated islet transplant data presented March 2026 from a 12-patient UChicago Medicine cohort treated with tegoprubart. All 10 patients >4 weeks post-transplant achieved insulin independence and mean HbA1c ~5.35%. No rejection, no de novo donor-specific HLA antibodies, and no nephrotoxicity, hypertension or neurotoxicity were observed. Tegoprubart was generally well tolerated and immunosuppression-related adverse events were managed by lowering mycophenolic acid dose.
Findings support CD40L blockade as a calcineurin inhibitor-free option for islet graft protection and inform planned regulatory engagement later in 2026.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced that the FDA granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation on March 10, 2026. Tegoprubart previously held orphan designations for pancreatic islet transplantation and ALS.
The company cites kidney transplant clinical studies and preclinical liver data supporting further evaluation, and anticipates an investigator-sponsored clinical trial to begin later in 2026.
NewcelX (Nasdaq: NCEL) announced a collaborative research agreement with Eledon Pharmaceuticals (Nasdaq: ELDN) to evaluate combination strategies pairing NewcelX's lead stem-cell-derived islet program, NCEL-101, with Eledon's anti-CD40L antibody tegoprubart (AT-1501).
The collaboration leverages clinical experience from >100 transplant patients treated with tegoprubart and aims to support durable, immune-protected islet replacement, potentially clarifying regulatory pathways and accelerating NCEL-101 development toward pivotal milestones.
Eledon Pharmaceuticals (Nasdaq: ELDN) will participate in the Leerink Partners 2026 Global Healthcare Conference.
Chief Executive Officer David-Alexandre C. Gros, M.D. and President & Chief Scientific Officer Steven Perrin, Ph.D. will appear in a fireside chat on March 11, 2026 at 1:40 p.m. ET. A live webcast requires advance registration and a replay will be posted under Events on the company website.
Eledon (Nasdaq: ELDN) announced that Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 10:00 a.m. ET (7:00 a.m. PT).
According to the company, the session will be webcast live with a replay available afterward on Eledon’s website under Events.